2 news · updated Jul 20, 2026

Samsung Biologics GSK

2026-07-19

Samsung Biologics to launch $1.8 billion all-cash bid for PolyPeptide

Samsung Biologics plans a $1.8 billion cash acquisition of Swiss drugmaker PolyPeptide to expand capabilities in peptide-based therapeutics like GLP-1 drugs. The offer includes a 6.1% premium and aims

reuters · 2026-07-19 17:16 UTC

2026-04-03

Samsung Biologics completes $280M acquisition of GSK manufacturing facility in Maryland

Samsung Biologics completed a $280M acquisition of a GSK manufacturing facility in Maryland, marking the company's first manufacturing presence in the United States.

chemweek · 2026-04-03 18:18 UTC

Samsung Biologics GSK

Samsung Biologics to launch $1.8 billion all-cash bid for PolyPeptide

Samsung Biologics completes $280M acquisition of GSK manufacturing facility in Maryland

Media coverage (2)

Related topics